ReviewCurrent cancer drug targets2026

Synergistic Targeting of EGFR, ESR1, BCL2, and TP53 Pathways: A Multi-Pronged Approach for Advanced Breast Cancer Therapy.

Harneet Marwah et al.PubMed ↗Publisher ↗

No numbers read from the abstract.